Rivaroxaban Benefits PAD Patients, With or Without Clopidogrel, Substudy Shows
A substudy from the VOYAGER PAD trial shows that low-dose rivaroxaban is safe and effective in patients with peripheral arterial disease (PAD) undergoing revascularization, irrespective of clopidogrel use, according to late-breaking trial results presented Sunday at the American College of Cardiology (ACC) Scientific Sessions 2020 virtual conference.